Mitochondrial-derived tRNA fragment (mt-tRF)

Mitochondrial-derived tRNA fragments (mt-tRFs) are a diverse class of small non-coding RNAs, typically 14 to 50 nucleotides in length, generated through the site-specific cleavage of mitochondrial-encoded transfer RNAs (Meseguer, S., 2021, Frontiers in Molecular Biosciences). These fragments function as potent regulators of cellular physiology by modulating post-transcriptional gene expression, often by mimicking microRNAs or by sequestering RNA-binding proteins such as Argonaute (Loher, P., et al., 2017, Scientific Reports). They are increasingly recognized for their roles in mitochondrial-nuclear retrograde signaling, allowing the organelle to communicate its metabolic status to the nucleus to coordinate stress responses (Telonis, A. G., et al., 2015, Oncotarget). In clinical contexts, dysregulated mt-tRF expression is linked to various pathologies, including breast and prostate cancers, where they can promote cell proliferation and survival (Guzman, N., et al., 2015, BMC Cancer). Furthermore, specific mt-tRFs are altered in neurodegenerative diseases like Alzheimer's, suggesting they may contribute to the mitochondrial dysfunction characteristic of these conditions (Wu, W., et al., 2021, Journal of Alzheimer's Disease). As therapeutic targets, mt-tRFs are being explored through the use of antisense oligonucleotides to silence pathogenic fragments or synthetic mimics to replenish those with protective functions. Their stability in biofluids also positions them as promising non-invasive biomarkers for the early detection and monitoring of metabolic and oncological diseases.

Other names

Mitochondrial-originated tRNA fragmentmt-tRFmt-tDRMitochondrial tRNA-derived small RNAmtsRNAMitochondrial tRNA-derived fragment

Antisense-mediated degradation of oncogenic fragments; Replacement therapy using synthetic mimics to restore tumor-suppressive function; Competitive inhibition of RNA-binding protein interactions to modulate translation.